Published in Urology on August 01, 2000
Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men. Urology (2012) 1.44
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int (2013) 1.39
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer (2013) 1.37
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
Emerging PSA-based tests to improve screening. Urol Clin North Am (2014) 0.94
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomark Cancer (2016) 0.92
Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. J Am Chem Soc (2008) 0.87
PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol (2010) 0.87
BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia. Rev Urol (2005) 0.83
How Precisely Can Prostate Cancer Be Managed? Int Neurourol J (2016) 0.83
Prostate cancer detection upon transrectal ultrasound-guided biopsy in relation to digital rectal examination and prostate-specific antigen level: what to expect in the Chinese population? Asian J Androl (2015) 0.82
Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men. J Urol (2011) 0.80
PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml (-1) and 10.1-20.0 ng ml (-1) : a multicenter study. Asian J Androl (2015) 0.79
A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies. Int Urol Nephrol (2009) 0.79
Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). World J Urol (2015) 0.77
Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. PLoS One (2015) 0.77
MicroRNA Regulating Glutathione S-Transferase P1 in Prostate Cancer. Curr Pharmacol Rep (2015) 0.76
Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. Insights Imaging (2016) 0.76
Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men. Open Biochem J (2015) 0.75
A pilot study on percent free prostate specific antigen as an additional tool in prostate cancer screening. Malays J Med Sci (2009) 0.75
New Progress of Epigenetic Biomarkers in Urological Cancer. Dis Markers (2016) 0.75
The use of a gas chromatography-sensor system combined with advanced statistical methods, towards the diagnosis of urological malignancies. J Breath Res (2016) 0.75
Measurement of serum prostate cancer markers using a nanopore thin film based optofluidic chip. Biosens Bioelectron (2015) 0.75
Clinical Significance of (18)F-Fluorodeoxyglucose Avid Prostate Gland Incidentalomas on Positron Emission Tomography/Computed Tomography. Mol Imaging Radionucl Ther (2017) 0.75
The f/t-PSA ratio in diagnosis of in-patients and out-patients: a unitary cutoff value is not useful! World J Urol (2009) 0.75
Association between Serum Testosterone and PSA Levels in Middle-Aged Healthy Men from the General Population. Curr Urol (2017) 0.75
Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4-10 ng/ml. World J Urol (2004) 0.75
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (1998) 8.33
The development of human benign prostatic hyperplasia with age. J Urol (1984) 8.29
Difficult Airway Society Guidelines for the management of tracheal extubation. Anaesthesia (2012) 7.19
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med (1992) 7.16
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med (1996) 5.06
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol (1999) 4.78
Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys (1999) 4.72
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Impotence following radical prostatectomy: insight into etiology and prevention. J Urol (1982) 4.08
The frequency of uterine leiomyomas. Am J Clin Pathol (1990) 4.00
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol (2001) 3.55
Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate (1983) 3.53
Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A (1992) 3.28
Family history and the risk of prostate cancer. Prostate (1990) 3.27
Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A (1997) 3.22
Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther (2012) 3.22
Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol (1999) 3.19
Randomized clinical trial of early laparoscopy in the management of acute non-specific abdominal pain. Br J Surg (1999) 3.18
Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol (1994) 3.17
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med (1993) 2.77
Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA (1996) 2.74
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA (1997) 2.73
Lyme arthritis in the Hunter Valley. Med J Aust (1982) 2.68
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging. Ann Surg Oncol (2009) 2.67
Biology and management of bladder cancer. N Engl J Med (1990) 2.60
Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (1999) 2.58
Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol (2003) 2.57
Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle. J Biol Chem (1997) 2.54
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst (1994) 2.50
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J (2002) 2.49
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
Factors predicting recovery of erections after radical prostatectomy. J Urol (2000) 2.44
Risk factors for urinary incontinence after radical prostatectomy. J Urol (1996) 2.42
Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer (1993) 2.40
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia (2011) 2.28
Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med (1974) 2.27
Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sources. Proc Natl Acad Sci U S A (1985) 2.26
Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health (2007) 2.25
The surgical implications of herniation of the urinary bladder. Arch Surg (1985) 2.23
Transperineal magnetic resonance image guided prostate biopsy. J Urol (2000) 2.21
Fewer sore throats and a better seal: why routine manometry for laryngeal mask airways must become the standard of care. Anaesthesia (2014) 2.21
A randomised controlled trial of cognitive behaviour therapy and motivational interviewing for people with Type 1 diabetes mellitus with persistent sub-optimal glycaemic control: a Diabetes and Psychological Therapies (ADaPT) study. Health Technol Assess (2010) 2.20
Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (1995) 2.19
Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia (2003) 2.18
Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. Int J Epidemiol (2005) 2.16
The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer (1998) 2.14
Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J Med Genet (2009) 2.13
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst (1997) 2.07
Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet (1981) 2.06
Prostate-specific antigen: what's new in 1997. Oncology (Williston Park) (1997) 2.06
Screening for prostatic carcinoma with prostate specific antigen. J Urol (1992) 2.03
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol (1999) 2.00
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
Synergistic gangrene of the scrotum and penis secondary to colorectal disease. J Urol (1978) 1.99
Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res (1996) 1.98
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol (1996) 1.98
Neutral-lipid storage disease: a new disorder of lipid metabolism. Br Med J (1975) 1.97
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res (1998) 1.95
Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science (1991) 1.93